6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November , 2003
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 18 November, 2003 By Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
19 NOVEMBER 2003

NOVOGEN GRANTED US PATENT COVERING PHENOXODIOL FOR CANCER
TREATMENT.
Pharmaceutical company Novogen, has been granted the
US patent covering methods for treating all Benign and
malignant cancers with the anti cancer drug phenoxodiol,
including ovarian cancer, breast cancer, prostate cancer
and cervical cancer.

Phenoxodiol is currently in phase II human clinical trials
in the US and Australia, and the rights to commercialise
phenoxodiol have been licensed to the Novogen
majority owned US company Marshall Edwards, Inc.

Managing Director of Novogen, Mr Christopher Naughton,
said the latest US patent joined a suite of existing
protection which consolidated and further secured Novogens
intellectual property position.

Novogen has a leading position in the research and
development of drugs derived from its phenolic
technology platform.

The Company manages its international research and
development programs utilising the expertise and
clinical research capabilities of universities and
hospitals in the US, Australia and other key
international locations.

The oncology compound phenoxodiol is being developed
by the Companys listed subsidiary Marshall Edwards, Inc.
LSE-AIM:MSH).

More information on phenoxodiol and on the Novogen
group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com .

Statements herein that are not descriptions of historical facts
are forward-looking and subject to risk and uncertainties.
Actual results could differ materially from those currently
anticipated due to a number of factors, including those set
forth in the Company's Securities and Exchange Commission
filings under "Risk Factors", including risks
relating to the early stage of products under development;
uncertainties relating to clinical trials; dependence on third
parties; future capital needs; and risks relating to the
commercialisation, if any, of the Company's proposed products
(such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks).

Novogen is a world leader in the research and development of
drugs derived from its phenolic technology platform. The
company manages its international research and development
programs utilising the expertise and clinical research
capabilities of universities and hospitals in the US,
Australia and other key international locations.
The oncology compound phenoxodiol is being developed
by the Company's listed subsidiary Marshall Edwards Inc.
(LSE-AIM:MSH).

More information on phenoxodiol and on the Company can be
found at www.marshalledwardsinc.com and www.novogen.com .

ISSUED FOR : NOVOGEN LIMITED
LISTINGS : ASX (CODE NRT), NASDAQ
(CODE NVGN).
FOR FURTHER CHRISTOPHER NAUGHTON,
MANAGING DIRECTOR, NOVOGEN LIMITED
INFORMATION : TEL (02) 9878 0088

ISSUED BY : WESTBROOK COMMUNICATIONS
CONTACT: DAVID REID TEL (02)
9231 0922 OR
0417 217 157